Brassinosteroids are growth-promoting hormones with key roles in plant development ([@r1]). They are sensed by the receptor kinase with leucine-rich repeat ectodomain (LRR-RK) BRASSINOSTEROID INSENSITIVE 1 (BRI1) that is composed of a LRR ectodomain, a single membrane-spanning helix, and a cytoplasmic kinase module ([@r2], [@r3]). BRI1 directly binds brassinosteroids including the potent brassinolide (BL) ([@r4]). The steroid binding site is formed by the BRI1 LRR core and by the island domain inserted between LRRs 21 and 22 ([@r5], [@r6]). Steroid binding creates a docking platform for the LRR ectodomain of a member of the SOMATIC EMBRYOGENESIS RECEPTOR KINASE (SERK) family of coreceptor kinases ([*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)) ([@r6][@r7][@r8]--[@r9]). BRI1 forms a ligand-dependent heterodimeric complex with a SERK protein in vitro, with the SERK N-terminal capping domain completing the steroid binding pocket ([@r10][@r11]--[@r12]). Receptor--coreceptor complex formation at the cell surface brings the cytoplasmic domains of BRI1 and SERK in close proximity, allowing for transphosphorylation of the two kinases and activation of the brassinosteroid signaling pathway ([@r11], [@r13], [@r14]). The sequence-related LRR-RK HAESA shares the overall architecture with BRI1 but lacks the island domain ([@r15]). HAESA and HAESA-LIKE 2 (HSL2) bind the peptide hormone INFLORESCENCE DEFICIENT IN ABSCISSION (IDA) to trigger abscission of floral organs in *Arabidopsis* and both receptors associate with SERKs in an IDA-dependent manner ([@r16][@r17]--[@r18]). HAESA/HSL2 and BRI1 bind drastically different ligands using different surface areas of their ectodomains. However, both receptors rely on the same SERK proteins for activation and the three-dimensional structures of the active signaling complexes are remarkably similar ([@r11], [@r17], [@r19]) ([Fig. 1*A*](#fig01){ref-type="fig"}). In addition, SERK proteins have been genetically and biochemically implicated in many other LRR-RK signaling pathways ([@r20]). How few SERK proteins allow for sensing of many different small molecule, peptide, and protein ligands and to the activation of their cognate receptors remains to be investigated. Here we analyze how SERKs can contribute to the specific binding of BL and IDA and to the activation of BRI1 and HAESA.

![Two distinct SERK surface patches contribute to formation of different LRR-RK complexes. (*A*, *Center*) Structural superposition of BRI1--BL--SERK1 (PDB ID 4LSX) and HAESA--IDA--SERK1 (PDB ID 5IYX) complex structures, using the SERK1 ectodomain as reference (rmsd is ∼0.6 Å comparing 185 corresponding C~α~ atoms). Shown are C~α~ traces of the BRI1 LRR domain (blue, island domain in dark blue), the HAESA LRR domain (orange), the SERK1 ectodomain (gray) and the steroid (blue) and peptide (orange) ligands in surface representation, respectively. (*A*, *Left*) Close-up view of the BRI1--BL--SERK1 complex, highlighting the two distinct interaction surfaces and including selected interface interactions. BL is shown in bond representation (yellow). (*A*, *Right*) Details of the HAESA--IDA--SERK1 interface, with IDA shown in bonds representation (yellow). SERK residue numbering is according to *Arabidopsis* SERK3. (*B*) Grating-coupled interferometry (GCI)-derived binding kinetics for BRI1 and HAESA vs. their ligands and SERK3. Shown are sensorgrams with data in red and their respective fits in black ([*Materials and Methods*](#s3){ref-type="sec"}). Table summaries of kinetic parameters are shown (*k*~a~, association rate constant; *k*~d~, dissociation rate constant; *K*~D~, dissociation constant). (*C*) Isothermal titration calorimetry (ITC) of the BRI1 LRR domain vs. wild-type and mutant SERK3 ectodomains and in the presence of BL. (*D*) ITC of the HAESA LRR domain vs. SERK3 proteins and in the presence of IDA. Table summaries for dissociation constants (*K*~D~) and binding stoichiometries (N) are shown (± fitting error; n.d., no detectable binding).](pnas.1714972115fig01){#fig01}

Results {#s1}
=======

A structural superposition of the previously reported BRI1--BL--SERK1 and HAESA--IDA--SERK1 complexes using the SERK1 ectodomain as reference \[root mean square deviation (rmsd) is ∼0.6 Å comparing 185 corresponding C~α~ atoms\] reveals that SERKs bind BRI1 and HAESA in similar positions, despite their drastically different ligand binding sites ([Fig. 1*A*](#fig01){ref-type="fig"}) ([@r11], [@r17], [@r20]). To characterize the interactions of BRI1 and HAESA with their ligands and coreceptors, we determined binding kinetics using a label-free surface biosensor based on grating-coupled interferometry (GCI) ([*Materials and Methods*](#s3){ref-type="sec"}) ([@r21]). In addition, steady-state binding constants were derived from isothermal titration calorimetry (ITC) experiments. We found that BL binds BRI1 with a dissociation constant (*K*~D~) of ∼10 nM in GCI assays, similar to the previously reported binding affinity for radio-labeled BL interacting with BRI1-containing plant membrane fractions ([Fig. 1*B*](#fig01){ref-type="fig"}) ([@r4]). This tight interaction of the steroid with its receptor is characterized by a fast association rate (*k*~a~ ∼ 1·10^6^ M^−1^⋅s^−1^) and a relatively slow dissociation rate (*k*~d~ ∼ 1·10^−2^⋅s^−1^). HAESA, in contrast, binds the IDA peptide with a *K*~D~ of ∼30 μM ([Fig. 1*B*](#fig01){ref-type="fig"}), which is in good agreement with the previously reported *K*~D~ determined by ITC ([@r17]). IDA rapidly associates with its receptor (*k*~a~ ∼ 6·10^4^ M^−1^⋅s^−1^), but in contrast to the steroid hormone the peptide has a fast dissociation rate (*k*~d~ ∼ 2 s^−1^). Our kinetic analyses reveal that BRI1 and HAESA have evolved distinct modes of ligand binding, allowing them to sense steroid and peptide ligands with very different binding kinetics.

We assessed binding of the coreceptor SERK3 to the ligand-bound BRI1 and HAESA ectodomains. SERK3 is a bona fide BRI1 and HAESA coreceptor ([@r8], [@r19], [@r22]) and its ectodomain can be produced in sufficient quantities for biochemical studies ([*SI Appendix*, Fig. S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). BRI1 shows no detectable binding to SERK3 in the absence of BL in vitro ([@r11]). In the presence of BL, SERK3 binds BRI1 with a *K*~D~ of ∼0.7 μM (GCI) or ∼0.2 μM (ITC), and with 1:1 stoichiometry ([Fig. 1 *B* and *C*](#fig01){ref-type="fig"}). SERK3 binds HAESA--IDA with a *K*~D~ of ∼0.2--1.5 μM as concluded from ITC ([Fig. 1*D*](#fig01){ref-type="fig"}) or GCI ([Fig. 1*B*](#fig01){ref-type="fig"}) experiments, respectively. The HAESA coreceptor SERK1 shows similar binding affinities ([@r17]). The kinetic parameters derived from the GCI experiments indicate that SERK3 binds BRI1 and HAESA in similar ways, with a relatively slow dissociation rate (*k*~d~ ∼ 1--3 × 10^−2^⋅s^−1^) ([Fig. 1*B*](#fig01){ref-type="fig"}). The observed dissociation rates for SERK3 binding to BRI1/HAESA may be sufficiently long to allow for the receptor and coreceptor kinase domains to transphosporylate and activate each other in the cytosol ([@r11], [@r13]), as previously speculated ([@r20]).

We next analyzed which SERK residues interact with either the ligand or the cognate receptor in the previously reported BRI1--BL--SERK1 ([@r11]) and HAESA--IDA--SERK1 ([@r17]) complexes. Residues originating from the SERK N-terminal capping domain are in direct contact with the steroid and the peptide hormone, but different residues are used to recognize the respective ligands ([Fig. 1*A*](#fig01){ref-type="fig"}) ([@r11], [@r17]). In the case of BRI1, Phe60 (all amino acid numbering refers to SERK3) establishes a π-stacking interaction with the C ring of brassinolide, while side-chain and main-chain atoms from His61 and Trp59 are hydrogen bonding with the 2α--3α diol moiety of the ligand ([@r6], [@r11], [@r12]). In the case of HAESA, SERK residues Thr52 and Val54 form main-chain contacts with the conserved C terminus of the peptide hormone, with Phe60 and His61 not being part of the IDA binding site ([Fig. 1*A*](#fig01){ref-type="fig"}) ([@r17]). Mutation of Phe60 and/or His61 to Ala completely disrupts binding of SERK3 to BRI1--BL, suggesting that interactions between coreceptor and steroid hormone are critical for receptor--coreceptor complex formation ([Fig. 1*C*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Importantly, SERK3^F60A/H61A^ can still bind HAESA--IDA with moderately reduced affinity ([Fig. 1*D*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)).

As IDA establishes only main-chain contacts with the SERK3 N-terminal cap loop, we replaced either Thr52 or Val54 with a bulky phenylalanine. While SERK3^T52F^ still binds BRI1 and HAESA with wild-type affinity ([*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)), mutation of Val54 to Phe selectively reduces binding of the mutant SERK3 protein to HAESA, but not to BRI1 ([Fig. 1*B*](#fig01){ref-type="fig"}). Thus, structure-based point mutations in SERK3 can selectively inhibit binding to either BRI1 or HAESA, highlighting that different surface patches in the SERK N-terminal cap can indeed allow for the sensing of specific ligands in different LRR-RK complexes ([Fig. 1](#fig01){ref-type="fig"}) ([@r11], [@r17], [@r20]).

In addition to SERKs forming part of the steroid and peptide hormone binding site, a direct receptor--coreceptor interface can be observed in the ternary complexes ([@r11], [@r12], [@r17]). In the case of BRI1, the interface involves SERK^Y100^ that contacts BRI1^Q747^. SERK^Y124^ and SERK^R146^ are making extensive polar interactions with BRI1^E749^. Phe144 in SERKs forms hydrophobic contacts with BRI1^Y765^ ([Fig. 1*A*](#fig01){ref-type="fig"}). These residues are invariant among *Arabidopsis* SERK1--4 and among SERKs from other species, establish similar contacts in the HAESA--IDA--SERK1 complex ([Fig. 1*A*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)) ([@r17]), and are part of the receptor--coreceptor interface of related peptide hormone receptor complexes ([@r23][@r24]--[@r25]). Mutation of SERK3^F144^ to alanine has no drastic effect on BRI1--BL--SERK3 and HAESA--IDA--SERK3 interaction, but a SERK3^Y100A/Y124A^ double mutant shows reduced binding to either BRI1--BL or HAESA--IDA ([Fig. 1](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Thus, two different surface areas of the SERK ectodomain contribute to LRR-RK ligand sensing and complex formation.

To assess the contribution of the SERK mutations analyzed in vitro to brassinosteroid signaling, we created stable transgenic lines expressing either wild-type or mutant SERK3 from a genomic construct under control of its native promoter and in a *serk1-1 serk3-1* mutant background ([*SI Appendix*, Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Individual lines showing similar SERK3 protein levels were selected for subsequent analysis (compare [*SI Appendix*, Fig. S4*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). We did not quantify the effects of SERK3 point mutations on HAESA-mediated floral abscission, as detection of weak phenotypes is difficult in the established petal break-strength assay ([@r17]) and because higher-order SERK mutants display pleiotropic phenotypes at flowering stage ([@r19], [@r26]). The ability to complement the *serk1 serk3* brassinosteroid signaling phenotype was evaluated in a quantitative hypocotyl growth assay ([*SI Appendix*, *SI Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). In agreement with our biochemical experiments, mutation of Phe60 and/or His61 to alanine inactivates SERK3 brassinosteroid coreceptor function in planta ([Fig. 2 *A* and *B*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)) and disrupts receptor--coreceptor complex formation in vivo, as judged from coimmunoprecipitation (co-IP) experiments ([Fig. 2*D*](#fig02){ref-type="fig"}). Mutation of SERK3 residues targeting the direct receptor--coreceptor interface results in moderate-to-severe brassinosteroid signaling defects, with SERK3^Y100A/Y124A^ having the strongest effect ([Fig. 2 *A* and *B*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). This is in line with our biochemical findings, and our in vivo co-IPs confirm an important contribution of this direct receptor--coreceptor interface to BRI1 signaling complex integrity ([Figs. 1*C*](#fig01){ref-type="fig"} and [2*D*](#fig02){ref-type="fig"} and [*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)).

![Mutations in the SERK3 ligand binding and receptor interfaces differentially impact SERK3 function and complex formation in vivo. (*A*) Hypocotyl growth assay in the presence and absence of the brassinosteroid biosynthesis inhibitor brassinazole (BRZ), from seedlings grown for 5 d in the dark. *Serk1-1 serk3-1* mutants are BRZ hypersensitive and this phenotype can be complemented by expressing SERK3 in the mutant background (Col-0, untransformed wild type, *n* = 50). (*B*) Quantification of the data from *A*. The log-transformed endpoint hypocotyl length was analyzed by a mixed effects model for the ratio of the transgenic lines vs. wild type, allowing for heterogeneous variances. The ratio of the untreated and BRZ-treated hypocotyl length was calculated for wild type (rwt) and each mutant line (rm); the ratio of this ratio for wild type divided by the ratio for a given mutant line results in the ratio of ratios (RR = rwt/rm; CI, confidence interval). (*C*) Coimmunoprecipitation (Co-IP) of lines shown in *A*. SERK3:HA was immunoprecipitated from plant protein extracts using an anti-HA antibody (IP-HA) and BRI1 was detected with an anti-BRI1 antibody ([@r14]) in the IP elution.](pnas.1714972115fig02){#fig02}

We next tested in a formal genetic way whether the receptor--coreceptor heteromers observed in vivo, in biochemical assays and in crystals are required for brassinosteroid signal activation ([@r11], [@r14], [@r27]). We created protein chimera between BRI1 and SERK3, in which the kinase domain of the receptor is swapped with that of the coreceptor and vice versa and expressed them under the control of either the BRI1 or SERK3 promoter in *Arabidopsis* ([Fig. 3*A*](#fig03){ref-type="fig"} and [*SI Appendix*, Figs. S4 and S6 and Tables S1 and S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Expression of both chimeric constructs together partially complements the *bri1-301* ([*SI Appendix*, Fig. S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)) mutant in phenotypic and quantitative assays ([@r28]) ([Fig. 3 *B* and *C*](#fig03){ref-type="fig"} and [*SI Appendix*, Figs. S4 and S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Individual chimera cause dominant negative effects, corresponding to the mutant phenotype of their respective ectodomain: o(utside)BRI1--i(nside)SERK3 alone causes a *bri1* mutant phenotype ([Fig. 3*B*](#fig03){ref-type="fig"} and [*SI Appendix*, Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). oSERK3--iBRI1 plants are dwarf and show early senescence, reminiscent of *serk1 serk3 serk4* triple mutants ([Fig. 3*B*](#fig03){ref-type="fig"} and [*SI Appendix*, Figs. S4 and S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Together, these experiments support an essential role for BRI1--SERK heteromers in brassinosteroid signaling.

![BRI1 receptor activation requires heteromerization with a SERK coreceptor in planta. (*A*) Schematic view of signaling competent wild-type and chimeric BRI1--BL--SERK3 complexes. BRI1 domains are shown in blue, SERK3 domains in gray. (*B*) Stable transgenic lines expressing oBRI1--iSERK3:mCherry under the BRI promoter (pBRI1) and oSERK3--iBRI1:mCitrine under the SERK3 promoter (pSERK3) show a partially rescued *bri1-301* growth phenotype when expressed together (*Bottom Left*). The expression of isolated chimera results in a dominant negative growth phenotype (*Bottom Middle* and *Right*). ∼WT corresponds to pBRI1::BRI1:mCitrine/*bri1-null*. (Scale bar, 1 cm.) (*C*) Hypocotyl growth assay in the presence and absence of BRZ (compare [Fig. 2*A*](#fig02){ref-type="fig"}). *bri1-301* is hypersensitive to BRZ, a phenotype that is partially complemented by the expression of oBRI1--iSERK3 and oSERK3--iBRI1. Quantifications are shown, analyzed as in [Fig. 2*B*](#fig02){ref-type="fig"}.](pnas.1714972115fig03){#fig03}

The structural and biochemical similarities between the BRI1--BL--SERK and HAESA--IDA--SERK signaling complexes prompted us to investigate whether the receptor activation mechanism is conserved among these pathways in planta ([Fig. 1*A*](#fig01){ref-type="fig"}). We complemented a *hae hsl2* mutant, which shows strong floral abscission defects ([@r18], [@r29]), with a chimeric receptor, in which the BRI1 ectodomain is fused to the HAESA cytoplasmic domain and expressed under control of the HAESA promoter ([Fig. 4*A*](#fig04){ref-type="fig"} and [*SI Appendix*, Fig. S6 and Tables S1 and S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). We found that in contrast to a kinase-inactive version (HAESA^D837N^), functional chimera can complement the *hae hsl2* abscission phenotype ([Fig. 4 *B* and *C*](#fig04){ref-type="fig"}). Notably, expression of full-length BRI1 under the control of the HAESA promoter does not induce floral abscission in the *hae hsl2* mutant ([*SI Appendix*, Fig. S8](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). We hypothesized that endogenous brassinosteroids bind to the oBRI1 ectodomain in the *Arabidopsis* abscission zone and allow for SERK complex formation and HAESA signaling. To test this hypothesis, we generated a BRI1--HAESA protein chimera, in which the ectodomain carries the Gly644Asp missense mutation, which has been previously characterized in *bri1-6* mutants ([@r30]). Brassinosteroid binding is disrupted in BRI1^G644D^ in in vitro binding assays ([*SI Appendix*, Fig. S9](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). A 2.6-Å crystal structure of the mutant protein revealed that the mutation does not affect the overall structure of BRI1 and leaves the conformation of the island domain intact, making the Gly644Asp mutation an ideal tool to specifically interfere with the ligand binding function of BRI1 in planta ([*SI Appendix*, Fig. S9 and Table S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Importantly, oBRI1^G644D^--iHAESA cannot complement the *hae hsl2* mutant phenotype, suggesting that indeed brassinosteroid sensing and complex formation occurs in the abscission zone. Our oBRI1--iHAESA chimera indicates that the cytoplasmic signaling specificity of HAESA is encoded in its kinase domain and not in its extracellular domain.

![The receptor's kinase domain encodes for the signaling specificity of LRR-RK pathways. (*A*) Schematic overview of the oBRI1--iHAESA chimera and its envisioned signaling complex (colors as in [Fig. 3*A*](#fig03){ref-type="fig"}; the HAESA kinase domain is shown in orange). (*B*) Inflorescences of ∼9-wk-old *Arabidopsis* plants. Abscission of floral organs is impaired in *hae hsl2* mutant plants compared with Col-0 wild type. (*C*) Box plots of BRI1--HAESA chimera vs. Col-0 and *hae hsl2* lines. In a quantitative petal break-strength assay, the force required to remove a petal at a given position on the inflorescence is measured in gram equivalents (for each position, at least 15 independent measurements were taken). Statistical analysis is shown in [*SI Appendix*, Table S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental).](pnas.1714972115fig04){#fig04}

Discussion {#s2}
==========

The five SERKs in *Arabidopsis* have emerged as essential coreceptor kinases for different LRR-RK signaling pathways, controlling plant growth, development, and immunity ([@r20]). In the known LRR-RK--SERK complex structures, residues originating from the SERK N-terminal capping domain contact different small molecule and peptide ligands when bound to their cognate receptor, while the SERK LRR core forms variable interactions with the C-terminal half of the respective ectodomain of the receptor ([@r11], [@r12], [@r17], [@r23][@r24]--[@r25]). Here, we used the SERK-dependent LRR-RKs BRI1 and HAESA to assess the relative contributions of both coreceptor interaction surfaces to high-affinity ligand sensing, to complex formation, and to complex stability.

In the present study, we focused on analyzing SERK residues contributing to LRR-RK complex formation. We found that different residues from the SERK N-terminal capping domain interact with both the steroid hormone BL and the peptide hormone IDA and we could generate SERK3 mutants that selectively bind either BRI1--BL or HAESA--IDA. We speculate that these residues allow SERKs to discriminate between ligand-associated and apo forms of their cognate receptors. However, the sequence motifs identified in our study are not uniquely used for BRI1 or HAESA recognition: The SERK3 Phe60/His61-containing surface patch critical for interaction with BRI1 is also important for SERK recruitment to the plant phytosulfokine receptor, another island-domain containing LRR-RK ([@r24]). In addition, the SERK3 Thr52--Val54 loop is not only in direct contact with the C terminus of the peptide hormone IDA, but also mediates interaction with the LRR-RK peptide ligands flg22 ([@r23]), Pep1 ([@r31]), RGF ([@r32]), and CLE41 ([@r25]). This suggests that very different ligands are recognized by SERKs using only few invariant structural motifs ([@r33]). The requirement of several conserved surface patches in SERK proteins interacting with different ligands on one hand, and establishing direct complex interactions on the other hand, may rationalize why the SERK ectodomain sequences are highly conserved throughout plant evolution ([*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Sequence variation alone thus cannot explain the fact that SERKs act only partially redundant in various developmental and immune signaling pathways, which may rather be caused by differences in expression and/or localization to specific membrane (nano) domains ([@r34], [@r35]).

The interaction of LRR-RK ectodomains has been quantified for selected ligands with dissociation constants spanning several orders of magnitude, ranging from the midmicromolar ([@r17], [@r24]) to the low-nanomolar range ([@r32], [@r36], [@r37]). In contrast, the reported *K*~D~s for the ligand-dependent SERK association with different receptors are very similar (∼0.2--1.5 μM) ([@r17], [@r25]). This indicates that differently shaped ligand binding pockets in LRR-RKs allow for specific sensing of chemically diverse ligands, but that the mode of coreceptor recruitment is conserved among the different signaling pathways. We characterized a second, direct receptor--coreceptor interface and found that it strongly contributes to BRI1--SERK3 complex stability ([Fig. 1](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). We speculate that SERKs target ligand-bound LRR-RKs using their N-terminal capping domain, and then form a larger, zipper-like interface with the receptor. The second, constitutive interface may stabilize the signaling-competent receptor--ligand--coreceptor complex. In this respect, it is of note that the dissociation rate *k*~d~ for IDA binding to the isolated HAESA ectodomain is much faster than the dissociation of SERK3 from the HAESA--IDA complex ([Fig. 1*B*](#fig01){ref-type="fig"}). Together with the structural observation that SERKs bind on top of LRR-RK ligand binding sites, this suggests that a main function of the coreceptor may be to slow down dissociation of ligands from the receptor. Our work reveals that SERKs have evolved as adapter proteins that allow LRR-RKs to transduce information across membranes without the need for major conformation rearrangements.

The analysis of BRI1--SERK3 protein chimera in stable transgenic lines now provides formal genetic support for a heteromeric brassinosteroid signaling complex, extending previous studies on FLS2--SERK3 chimera analyzed in a transient expression system ([@r38]). The observation that expression of oBRI1--iSERK3 or oSERK3--iBRI1 chimera in isolation causes dominant negative growth phenotypes is likely due to their ability to form signaling incompetent complexes with endogenous LRR-RK pathway components. It is of note that our oSERK3--iBRI1 phenotypes are reminiscent of those caused by expression of the isolated SERK3 ectodomain ([@r39]). Our BRI1--HAESA chimera can rescue abscission defects in *hae hsl2* mutant plants, suggesting that the activation mechanisms of BRI1 and HAESA are highly similar, and that the kinase domain of the receptor encodes the cytoplasmic signaling specificity of LRR-RK complexes. The recent finding that the rice immune receptor XA21 requires SERKs for activation ([@r40]) now rationalizes the earlier observation that a BRI1--XA21 chimera can trigger immune signaling upon BL sensing in rice cells ([@r41]). Based on our and previous findings ([@r38], [@r41]), LRR-RK receptor chimera could help in defining the functions of presently orphan receptor kinases and may represent useful tools to modulate plant growth and development in crops.

In conclusion, a ligand-induced and SERK-stabilized receptor--coreceptor heterodimer represents the minimal signaling unit of many LRR-RK complexes at the cell surface. It will now be interesting to define at the structural level, how the cytoplasmic kinase domains of receptor and coreceptor interact with each other in the cytosol. The detailed analysis of these interactions may enable us to understand the cytoplasmic signaling specificity of different LRR-RK pathways, and potentially, the signaling cross-talk between them ([@r42]).

Materials and Methods {#s3}
=====================

See [*SI Appendix*, *SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental) for complete details.

Grating Coupled Interferometry. {#s4}
-------------------------------

GCI experiments were performed with the Creoptix WAVE system (Creoptix AG), a label-free surface biosensor ([@r21]). The interaction between the BRI1 ectodomain and BL was measured using a 2PCH WAVEchip (long polycarboxylate matrix; Creoptix AG), while all other experiments were performed on a 2PCP WAVEchip (quasiplanar polycarboxylate surface; Creoptix AG). Chips were conditioned using borate buffer (100 mM sodium borate, pH 9.0, 1 M NaCl; Xantec), and the respective ligands were immobilized on the chip surface via a standard amine-coupling protocol, which consisted of a 7-min activation with a 1:1 mix of 400 mM *N*-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and 100 mM *N*-hydroxysuccinimide (both Xantec), followed by injection of the ligands BRI1 or HAESA (1--50 μg/mL) in 10 mM sodium acetate, pH 5.0 (Sigma) until the desired density was reached, and quenched with 1 M ethanolamine, pH 8.0 for 7 min (Xantec). Since SERK3 showed nonspecific binding on the surface, BSA (0.5% in 10 mM sodium acetate, pH 5.0; BSA from Roche) was used to passivate the surface between BRI1/HAESA injection and ethanolamine quenching. Kinetic analysis of the BRI1--BL interaction was performed at 25 °C with a 1:4 dilution series (five dilutions in duplicates) from 0.4 μM BL in sodium citrate buffer, pH 5.0, using citrate buffer, pH 5.0, as running buffer, blank injections for double referencing, and DMSO calibration for bulk correction. A typical kinetic analysis of the SERK3 interaction was performed at 25 °C with a 1:2 dilution series from 2 μM in citrate buffer, pH 5.0, with 100 nM BL or 20 μM IDA in 20 mM sodium citrate, pH 5.0, 250 mM NaCl, blank injections for double referencing, and DMSO calibration for bulk correction. For BRI1 interaction experiments, the running buffer was supplemented with 100 nM BL while IDA was supplied only in the blanks and samples. Data correction and analysis was performed with the Creoptix WAVEcontrol software (corrections applied: X and Y offset, DMSO calibration and double referencing). Data were fitted to either one-to-one binding models or mass-transport limited models, using bulk correction.

ITC. {#s5}
----

ITC experiments were performed at 25 °C using a Nano ITC (TA Instruments) with a 1.0-mL standard cell and a 250-μL titration syringe. Proteins were gel filtrated into ITC buffer (20 mM sodium citrate, pH 5.0, 150 mM NaCl) and Y-IDA (YVPIPPSA-Hyp-SKRHN) was dissolved in ITC buffer. A 10-mM BL stock solution in 100% (vol/vol) DMSO was diluted into ITC buffer. A typical experiment consisted of injecting 10-μL SERK3 wild-type or mutant protein aliquots (∼170 μM) into ∼17 μM BRI1 + 100 μM brassinolide or ∼20 μM HAESA + 200 μM IDA in the cell at 150-s intervals. ITC data were corrected for the heat of dilution by subtracting the mixing enthalpies for titrant solution injections into protein-free ITC buffer. Data were analyzed using the NanoAnalyze program (version 3.5) as provided by the manufacturer.

Plant Material and Generation of Transgenic Lines. {#s6}
--------------------------------------------------

*SERK3* and *BRI1* were amplified from *Arabidopsis thaliana* (ecotype Col-0) genomic DNA and mutations were introduced by site-directed mutagenesis ([*SI Appendix*, Table S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Synthetic genes were constructed for the BRI1--SERK3 and BRI1--HAESA chimera (Invitrogen GeneArt) ([*SI Appendix*, Fig. S4 and Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1714972115/-/DCSupplemental)). Binary vectors were assembled using the multisite Gateway technology (Thermo Fisher Scientific). All constructs were introduced into *Agrobacterium tumefaciens* strain pGV2260, and *Arabidopsis* plants were transformed using the floral dip method ([@r43]). Plants were transformed with two vectors at the same time to create double transgenic lines containing pBRI1::oBRI1--iSERK3:mCherry and pSERK3::oSERK3--iBRI1:mCitrine. GABI_134E10 was used as a *bri1*-null allele ([@r10]), plants were grown in 50% humidity, 21 °C, in a 16-h light/8-h dark cycle, and analyzed in T3 generation.
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